The HeathCare segment at
) has progressed well with its pipeline in the last few quarters.
The company witnessed several product approvals and label
expansions. The HeathCare segment provided a brief update on its
five new pipeline candidates.
These candidates are selected for accelerated development and
are expected to be in phase III studies by 2015. The candidates
are currently in phase I and phase II studies.
The first of these candidates is finerenone (BAY 94-8862). Bayer
is developing the candidate in a phase IIb study for the
treatment of worsening chronic heart failure, as well as diabetic
nephropathy. The candidate was found to be effective in reducing
cardiovascular mortality in patients suffering from heart
BAY 1021189 is another candidate at Bayer's targeting the
cardiology market. The company intends to initiate a phase IIb
study on the candidate in patients suffering from worsening
chronic heart failure by year end. Bayer is also developing
molidustat (BAY 85-3934) for cardio-renal syndrome.
Molidustat is currently being developed in a phase IIb study
for the treatment of patients suffering from anemia associated
with chronic kidney disease and/or end-stage renal disease. The
candidate performed encouragingly in phase I studies.
ALLERGAN INC (AGN): Free Stock Analysis
BAYER A G -ADR (BAYRY): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
Apart from the cardiology segment, Bayer also focuses on the
oncology and women's health areas. Bayer also chose copanlisib
(BAY 80-6946), an oncology candidate, for accelerated
development. The company is currently evaluating the candidate in
a phase II study in patients suffering from non-Hodgkin's
lymphoma. The candidate has performed well in preclinical and
phase I studies.
The final candidate under accelerated development is sPRM (BAY
1002670). Bayer is developing the candidate for treating patients
suffering from symptomatic uterine fibroids. Bayer expects to
initiate a phase III study on the candidate in mid-2014.
Bayer also provided an update on label expansion and further
studies on five of its approved products. Bayer's Xarelto is
approved for five indications including stroke prevention in
non-valvular atrial fibrillation, deep vein thrombosis (DVT),
pulmonary embolism (PE) and reducing the risk of recurrent DVT
and PE. Xarelto is also being developed for other cardiovascular
diseases in phase III studies.
The company is looking to expand labels of oncology drugs
Stivarga, anti-cancer drug Xofigo, pulmonary hypertension drug
Adempas and eye drug Eylea. We are encouraged by company's
efforts to develop its pipeline.
Bayer, a large-cap pharma company, presently carries a Zacks Rank
#2 (Buy) and so does other large-cap companies like
) looks more attractive with a Zacks Rank #1 (Strong Buy).